Bryan A. Baxter

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

Stephen A. Harrison, Stephen J. Rossi, Angelo H. Paredes et al. · Hepatology · 2019 · 251 citations · Full text

Liver Fibrosis, Immunology, Gastroenterology +24

140-LB: NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

Alex M. DePaoli, Phùng Văn Trung, Mustafa R. Bashir et al. · Diabetes · 2019 · 27 citations

Pinnacle Clinical Research, Fatty Liver Disease, Insulin Signaling +21

NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks

S. Harrison, Stephen J. Rossi, Mustafa R. Bashir et al. · Journal of Hepatology · 2018 · 12 citations

Fibrosis, Hepatology, Medicine +12